Skoči na glavni sadržaj

Reumatizam, Vol. 54 No. 2, 2007.

Izlaganje sa skupa

Etanercept (Enbrel®) - our experiences

Jadranka Morović-Vergles ; Zavod za kliničku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinička bolnica “Dubrava”, Zagreb, Hrvatska
Dušanka Martinović Kaliterna ; Odsjek za kliničku imunologiju i reumatologiju, Klinika za unutarnje bolesti, Klinički bolnički centar Split, Split, Hrvatska

Puni tekst: hrvatski pdf 426 Kb

str. 69-70

preuzimanja: 351

citiraj

Sažetak

Rheumatoid arthritis (RA) is a chronic, systemic disease. Female patients outnumber males in a ratio of 3:1. Cytokines and immune cells networks have been identified as important mediators in the pathogenesis and perpetuation of inflammation in RA. This information has been successfully used into the development of new and significantly more effective treatments, for example anticytokines agents. The goal in managing RA is to achieve remission. We report five patients with RA successfully treated with etanercept.

Ključne riječi

etanercept; rheumatoid arthritis; disease activity score 28 (DAS28)

Hrčak ID:

125352

URI

https://hrcak.srce.hr/125352

Datum izdavanja:

19.10.2007.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.813 *